RE:RE:RE:RE:RE:Trying to look at the positives Wino gave you a good and complete answer. R&D drops pretty quickly, even more so if TH-1902 never restarts, Trogarzo inventories continue to fall due to a credible, reliable new supplier (Samsung) allowing THTX to drammatically reduce inventory, as well as other cost cutting.
Cash was helped in the last quarter by the small ATM sale as well as inventory reduction with Trogarzo. I would not be surprised if we see more ATM sales at some point as well as they try to manage cash to keep them out of harms way with the Marathon debt agreement requirements. Which means if a size buyer wants in, the company might use the ATM to sell the shares they are looking for. Hopefully not at these low prices but I could certainly see that happening at some point, which does reduce the demand for the stock in the market and therefore resulting in a lower share price.
realitycheck4u wrote: "With no plan to reduce selling, administrative or R&D budget, I expect they will drain what remains of shareholders value before the end of the year."
I would like to know what the other large shareholders think of this.
houbahop wrote: ..."But the driver at this point and the future for the next 12 months is to prove to the skeptical market they are growing at 15% and will see a large drop-off in spend starting soon, thus bringing more cash to the operating profit line. It will be those financial metrics that will move the share from the ridiculous $1 to something closer to intrinsic value for a company selling close to $100mil in products and moving to profitability on the bottom line next year."...
I haven't seen any plan to reduce cost for 2023 and we are already 3 month into the year.
According to the last Financial report, Dubuc said:
As we maintain a tight control on expenses, it will be our strategic imperative to become Adjusted EBITDA positive in order to deliver strong shareholder returns.
In 2022 main expenses were:
- Selling: $39m
- General & Admin. : $17m
- R&D: $37m
What is the plan to control expenses?
Nothing substancial has been said on this most important issue.
But for Levesque, the way to achieve the goal is:
..."We are also actively working towards the identification of potential in-licensing, co-promotion, or immediately accretive product acquisitions in order to accelerate this journey towards positive Adjusted EBITDA"...
With no plan to reduce selling, administrative or R&D budget, I expect they will drain what remains of shareholders value before the end of the year.